Expertise in
16
conditions

Dr. Kyriakos Papadopoulos

Oncology
The Start Center For Cancer Care
4383 Medical Dr, 
San Antonio, TX 
Accepting New Patients
Expertise in
16
conditions
The Start Center For Cancer Care
4383 Medical Dr, 
San Antonio, TX 

Overview

Kyriakos Papadopoulos is an Oncologist practicing medicine in San Antonio, Texas.

Dr. Papadopoulos is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Adenoid Cystic Carcinoma, Salivary Gland Tumors, Breast Cancer, and Melanoma.

He is actively involved in clinical research, co-authoring 115 peer reviewed articles and participating in 10 clinical trials. Dr. Papadopoulos is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

The Start Center for Cancer Care
4383 Medical Dr, San Antonio, TX 78229

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drug: AVID100
Study Phase: Phase 1/Phase 2
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, PK, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Enrollment Status: Completed
Publish Date: May 03, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 27, 2023
Intervention Type: Drug
Study Drugs: SY-5609, Fulvestrant
Study Phase: Phase 1
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
A Phase 1b Study of INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
A Phase 1b/2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4/6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors With Expansion in Advanced Gastrointestinal Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Colorectal Cancer or in Combination With Encorafenib + Cetuximab in Subjects With BRAFV600E Mutated Advanced Colorectal Cancer
Enrollment Status: Unknown
Publish Date: January 26, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: March 09, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Enrollment Status: Terminated
Publish Date: February 01, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: August 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

115 Total Publications

Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Fusion oncoproteins and cooperating mutations define disease phenotypes in NUP98-rearranged leukemia.
Journal: Blood
Published: February 25, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Andrew Brenner
Oncology
Expertise in
18
conditions
Dr. Andrew Brenner
Oncology

University Of Texas Health Science Center At San Antonio

7979 Wurzbach Rd, 
San Antonio, TX 
 (0.4 miles away)
210-450-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Brenner is an Oncologist practicing medicine in San Antonio, Texas. Dr. Brenner is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Glioblastoma, Glioma, Colonoscopy, and Endoscopy.

Expertise in
11
conditions
Dr. Michael Liss
Oncology
Expertise in
11
conditions
Dr. Michael Liss
Oncology

Medical Arts Research Center At The UT Health

8300 Floyd Curl Dr, 
San Antonio, TX 
 (0.6 miles away)
210-450-9600
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Liss is an Oncologist practicing medicine in San Antonio, Texas. Dr. Liss is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Nephrectomy, and Prostatectomy.

Expertise in
31
conditions
Dr. Antonio Santillan
Oncology
Expertise in
31
conditions
Dr. Antonio Santillan
Oncology

Texas Oncology - San Antonio Medical Center

5206 Research Dr, 
San Antonio, TX 
 (2.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Antonio Santillan is an Oncologist practicing medicine in San Antonio, Texas. Dr. Santillan is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Oophorectomy, and Salpingo-Oophorectomy. Dr. Santillan is currently accepting new patients.

Frequently Asked Questions about Dr. Kyriakos Papadopoulos

Is Dr. Kyriakos Papadopoulos a top-rated expert for Adenoid Cystic Carcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kyriakos Papadopoulos is classified as an Distinguished expert for Adenoid Cystic Carcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kyriakos Papadopoulos specialize in?

While Dr. Kyriakos Papadopoulos is a Oncology, they have specific expertise in Adenoid Cystic Carcinoma, Salivary Gland Tumors, and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kyriakos Papadopoulos participate in research or clinical trials?

Yes. Dr. Kyriakos Papadopoulos has published 115 articles and abstracts on conditions like Adenoid Cystic Carcinoma. You can view a list of Dr. Kyriakos Papadopoulos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kyriakos Papadopoulos accept my insurance?

Dr. Kyriakos Papadopoulos accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Papadopoulos's expertise for a condition
ConditionClose
    View All 15 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile